t
Oxford Biomedica PLC (OXB) announced on March 4, 2026, that it applied to the London Stock Exchange for the admission to trading of 92,381 ordinary shares of 50 pence each. These shares were allotted under the OXB Long Term Incentive Plan, Sharesave Scheme, and Employee Share Option Scheme, and admission is expected to become effective on March 9, 2026, with the new shares ranking pari passu.
| Date | 4 Mar 2026 |
| Time | 11:45:00 |
| Category | Miscellaneous |
| ID | 3372V |
OXB
Admission to Trading Application
Oxford, UK - 04 March 2026: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces that application has been made to the London Stock Exchange for the admission to trading of 92,381 ordinary shares of 50 pence each in the Company (the "New Ordinary Shares").
The requested admission relates to ordinary shares which have been alloted under:
· OXB Long Term Incentive Plan (LTIP)
· OXB Sharesave Scheme (SAYE)
· OXB Employee Share Option Scheme (ESOS)
It is expected that admission becomes effective on 09 March 2026. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.
-Ends-
Enquiries:
OXB:
Natalie Walter, Chief Legal Officer and Group Company Secretary
T: +44 (0) 1865 783 000 / E: [email protected]
About OXB
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.